Jim Simons Aligos Therapeutics, Inc. Call Options Transaction History
Renaissance Technologies LLC
- $63.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALGS
# of Institutions
32Shares Held
37.7MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$137 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$121 Million0.08% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5MShares$94.5 Million0.0% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.12MShares$59 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY2.08MShares$39.2 Million0.01% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $751M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...